JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.
AZN vs. NVO: Which Stock Is the Better Value Option?